Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome-Reference-Cited by-同舟云学术

Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome

Published:2016-08 Issue:16 Volume:9 Page:1667-1676
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Adamo Marianna,Ariotti Sara,Costa Francesco,Curello Salvatore,Moschovitis Aris,de Vries Ton,White Harvey D.,Windecker Stephan,Valgimigli Marco

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Platelet GP IIB-IIIa blockers;Topol;Lancet,1999

2. Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes

3. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial;Valgimigli;J Am Coll Cardiol,2004

4. Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban;King;Vascul Pharmacol,2016

5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina;N Engl J Med,1998

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s);Journal of the American Heart Association;2023-12-19

2. Tirofiban-induced thrombocytopenia;Annals of Medicine;2023-07-13

3. The High Bleeding Risk Patient with Coronary Artery Disease;Cardiology Clinics;2020-11

4. Hemorrhagic risk in patients candidates for coronary angioplasty: how to define, identify and treat high-risk patients;G ITAL CARDIOL;2020

5. A Simple Clinical Pre-procedure Risk Model for Predicting Thrombocytopenia Associated With Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention;Frontiers in Pharmacology;2018-12-10